Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence

Research output: Contribution to journalArticlepeer-review

Abstract

​​ Tardive dyskinesia (TD) is a condition of potentially irreversible abnormal involuntary movements associated with dopamine receptor blocking agents, such as antipsychotics. While prevention is the best strategy, it is not always possible. This report outlines strategies to reduce TD symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).

Original languageEnglish (US)
JournalThe Journal of clinical psychiatry
Volume81
Issue number6
DOIs
StatePublished - Sep 29 2020

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence'. Together they form a unique fingerprint.

Cite this